New drug PIT565 enters human testing for rheumatoid arthritis

NCT ID NCT07029555

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This early-phase trial is testing a new drug, PIT565, in 57 adults with rheumatoid arthritis. The main goal is to check if the drug is safe and how the body processes it. Researchers will monitor side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PIT565
What this could lead to: If this early trial shows PIT565 is safe and tolerable, it could lead to larger studies testing whether it helps control rheumatoid arthritis symptoms.
What could go wrong: This is a very early phase 1 trial with only 57 people, focused on safety, not effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

Novartis Investigative Site

Pilar, Buenos Aires, B1629AHJ, Argentina
Novartis Investigative Site

CABA, C1181ACH, Argentina
Novartis Investigative Site

Sofia, 1618, Bulgaria
Novartis Investigative Site

Beijing, 100191, China
Novartis Investigative Site

Beijing, 100730, China
Novartis Investigative Site

Brest, 29200, France
Novartis Investigative Site

Le Kremlin-Bicêtre, 94275, France
Novartis Investigative Site

Paris, 75014, France
Novartis Investigative Site

Jena, Thuringia, 07740, Germany
Novartis Investigative Site

Mainz, 55131, Germany
Novartis Investigative Site

Szeged, 6725, Hungary
Novartis Investigative Site

Leiden, South Holland, 2333 CL, Netherlands
Novartis Investigative Site

Cluj-Napoca, Cluj, 400006, Romania
Novartis Investigative Site

Bucharest, 011658, Romania
Novartis Investigative Site

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site

Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.